{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-23-016177","form_type":"8-K","ticker":"CING","cik":"0001862150","company_name":"Cingulate Inc.","filed_at":"2023-05-10T23:59:59+00:00","discovered_at":"2026-05-14T18:03:41.344167+00:00","generated_at":"2026-06-15T07:08:06.038366+00:00","sec_items":["1.01","2.02","2.03","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Cingulate Q1 net loss $4.0M, cash $1.7M; secures additional $3M debt from WFIA","bullets":["Net loss $4.0M for Q1 2023, improved from $5.0M in Q1 2022; R&D expenses $2.1M (down 25% YoY).","Cash and equivalents $1.7M at March 31, 2023; expects funding into Q3 2023 with new $3M debt.","Received $3M additional debt from WFIA, increasing promissory note to $8M, unsecured at 15% interest, due Aug 2025.","Completed transfer of PTR manufacturing to Societal CDMO; Phase 3 adult dose-optimization results expected Q3 2023.","Entered joint commercialization agreement with Indegene for CTx-1301 upon FDA approval."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-23-016177","json":"https://secwatch.observer/filing/0001493152-23-016177.json","markdown":"https://secwatch.observer/filing/0001493152-23-016177.md","text":"https://secwatch.observer/filing/0001493152-23-016177.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1862150/000149315223016177/0001493152-23-016177-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1862150/000149315223016177/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-15T07:08:06.038366+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"f2065e8a83205094496bc0e2137927ce53995cc3","claim":"Cingulate Inc. reported financial results for the three months ended March 31, 2023.","evidence_excerpt":"Cingulate Inc. (NASDAQ: CING), a biopharmaceutical company utilizing its proprietary Precision Timed ReleaseTM (PTRTM) drug delivery platform technology to build and advance a pipeline of next-generation pharmaceutical products, today provided financial results for the three months ended March 31, 2023, as well as a clinical and business update.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1862150/000149315223016177/0001493152-23-016177-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the three months ended March 31, 2023"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"},{"claim_id":"989489961c916caa20e21474633a47dd158551a1","claim":"Cingulate Inc. amended Note with Werth Family Investment Associates LLC valued at from $5.0 million to $8.0 million (effective 2023-05-09).","evidence_excerpt":"On May 9, 2023, CTx executed an amended and restated promissory note (the “Note”) in favor of WFIA that increased the principal amount of the Original Note from $5.0 million to $8.0 million.","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1862150/000149315223016177/0001493152-23-016177-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"amendment"},{"label":"Agreement","value":"credit facility"},{"label":"Counterparty","value":"Werth Family Investment Associates LLC"},{"label":"Value","value":"from $5.0 million to $8.0 million"},{"label":"Effective","value":"2023-05-09"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}